We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+60.43%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$242M
AUM Growth
+$20.3M
Cap. Flow
-$14.2M
Cap. Flow %
-5.88%
Top 10 Hldgs %
67.89%
Holding
53
New
6
Increased
20
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.33M
2
TELA icon
TELA Bio
TELA
+$3.26M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.47M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.86M
5
LRMR icon
Larimar Therapeutics
LRMR
+$1.83M

Top Sells

Rank Stock Value
1
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.89M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$5.58M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.36M
4
MASS icon
908 Devices
MASS
+$3.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
26
LENZ Therapeutics
LENZ
$151M
$1.83M 0.76%
82,464
+16,750
+25% +$399K
THRX
27
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.28M 0.53%
220,650
+188,350
+583% +$1.33M
IMPL
28
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$1.24M 0.51%
255,250
+110,608
+76% +$847K
ATXS
29
DELISTED
Astria Therapeutics
ATXS
$1.21M 0.5%
+133,500
New +$895K
MODD icon
30
Modular Medical
MODD
$29.4M
$1.14M 0.47%
9,181
– –
ALLK
31
DELISTED
Allakos
ALLK
$939K 0.39%
+153,500
New +$643K
CMRX
32
DELISTED
Chimerix, Inc.
CMRX
$704K 0.29%
365,000
-1,065,000
-74% -$2.39M
DERM icon
33
Journey Medical
DERM
$213M
$638K 0.26%
259,293
+13,560
+6% +$46.2K
MOR
34
DELISTED
MorphoSys AG American Depositary Shares
MOR
$609K 0.25%
+121,015
New +$625K
FOCL
35
EDAP TMS S.A.
FOCL
$199M
$588K 0.24%
+71,300
New +$542K
NPCE icon
36
Neuropace
NPCE
$485M
$436K 0.18%
116,324
+26,224
+29% +$126K
LUMO
37
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$412K 0.17%
46,576
+25,056
+116% +$208K
NGNE icon
38
Neurogene
NGNE
$758M
$368K 0.15%
28,750
-1,750
-6% -$35.7K
OPTN
39
DELISTED
OptiNose
OPTN
$333K 0.14%
6,065
– –
MGTX icon
40
MeiraGTx Holdings
MGTX
$1.36B
$84K 0.03%
+10,000
New +$88.2K
IDYA icon
41
IDEAYA Biosciences
IDYA
$4.03B
$22K 0.01%
+1,500
New +$19.5K
BLRX
42
BioLineRX
BLRX
$12.1M
$16K 0.01%
417
– –
AVTX icon
43
Avalo Therapeutics
AVTX
$1.08B
– –
-156
Closed -$225K
CLDX icon
44
Celldex Therapeutics
CLDX
$3.18B
– –
-90,000
Closed -$2.43M
DNA icon
45
Ginkgo Bioworks
DNA
$489M
– –
-20,375
Closed -$1.94M
HYPR icon
46
Hyperfine
HYPR
$89.7M
– –
-763,075
Closed -$1.7M
KNSA icon
47
Kiniksa Pharmaceuticals
KNSA
$6.23B
– –
-814,250
Closed -$7.89M
MASS icon
48
908 Devices
MASS
$459M
– –
-166,406
Closed -$3.43M
MGNX icon
49
MacroGenics
MGNX
$260M
– –
-208,300
Closed -$614K
VSTM icon
50
Verastem
VSTM
$668M
– –
-132,500
Closed -$1.84M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2022 Portfolio in Review

As of Q3 2022, Opaleye Management held 53 positions worth $242M, up 9.1% from $222M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Opaleye Management withdrew a net $14.2M in Q3 2022, closing 11 positions and reducing 10 holdings. Its most notable exit was Kiniksa Pharmaceuticals, an estimated $7.89M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Astria Therapeutics worth $1.21M.

  • Opaleye Management's largest Q3 2022 buy was Astria Therapeutics: 133,500 shares worth $1.21M.
  • Opaleye Management added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $8.33M increase.
  • Opaleye Management's biggest Q3 2022 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.36M.
  • Opaleye Management fully exited Kiniksa Pharmaceuticals in Q3 2022, selling an estimated $7.89M.
  • Opaleye Management's ten largest holdings make up 68% of its $242M portfolio in Q3 2022.
  • Opaleye Management opened 6 new positions and closed 11 in Q3 2022.
  • Opaleye Management's portfolio value rose 9.1% quarter-over-quarter to $242M.

Based on Opaleye Management's 13F filing for Q3 2022, filed 14 Nov 2022.